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Abstract
I In nt tr ro od du uc ct ti io on n: :   Evaluation of growth hormone (GH) in short thalassaemic patients
and effect of L-carnitine therapy in those with hormone deficiency.
M Ma at te er ri ia al l   a an nd d   m me et th ho od ds s: :   The study included 30 β-thalassaemic patients aged 13.8
ﾱ1.7 years and 30 children with constitutional short stature as controls.
Anthropometric measurements (basal and after 6 months), thyroid profile,
insulin-like growth factor-1 (IGF-1) and GH provocation by 2 tests were carried
out. Eight patients with inadequate GH response to both clonidine and ITT were
given L-carnitine treatment for 6 months. They were re-evaluated (clinically,
anthropometrically and in the laboratory by doing GH stimulation test) after 
6 months of therapy.
R Re es su ul lt ts s: :   Twelve (40%) patients had sub-clinical hypothyroidism and 10 (33.3%)
had growth hormone deficiency (GHD). Peak GH and growth velocity (cm and
standard deviation score [SDS]) were significantly lower while weight (SDS) and
weight/height SDS were significantly higher than in patients with constitutional
short stature (p < 0.05). A significant positive correlation was found between
height and target height (cm). Haemoglobin levels, peak GH, IGF-1 and growth
velocity  (cm  &  SDS)  were  significantly  higher  and  the  number  of  blood
transfusions was significantly lower in GH deficiency patients after L-carnitine
treatment (p < 0.05). Delta changes were higher in height (cm & SDS), estimated
mature height and sitting height and lower in target height – height (SDS and cm)
six months after L-carnitine treatment in β-thalassaemic patients with GHD 
(p < 0.05).
C Co on nc cl lu us si io on ns s: :   Growth hormone deficiency is an aetiological factor in thalassaemic
patients with short stature. L-carnitine can promote GH secretion and growth.
K Ke ey y   w wo or rd ds s: :   thalassaemia, growth hormone, L-carnitine treatment.
Introduction
Patients with multi-transfused thalassaemia major may develop severe
endocrine complications due to iron overload. The anterior pituitary is
particularly sensitive to iron overload, which disrupts hormonal secretion
resulting in hypogonadism, short stature, acquired hypothyroidism and
hypoparathyroidism. Glucose intolerance and diabetes mellitus are also
common [1].
Growth failure has been attributed to growth hormone deficiency (GHD),
hypothyroidism, delayed sexual maturation and hypogonadism [2]. The
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role of growth hormone (GH) in growth retardation
is controversial. Low insulin-like growth factor-1
(IGF-1) level has been suspected as being related
to either reduced spontaneous growth hormone
secretion, hepatic damage or growth hormone
insensitivity. The treatment of stunted thalassaemic
patients with physiological GH doses seems to be
inefficient,  indicating  that  other  factors  are
responsible for this type of growth retardation [3, 4].
Carnitine is a natural substance synthesized in
the liver, brain and kidney from protein bound lysine
and methionine. The final synthetic step occurs in
the liver [5]. It is present in all tissues and several
factors such as sex hormones and glucagon may
impact on carnitine distribution and level in tissues.
Many authors have reported that failure to thrive
and  developmental  delay  are  associated  with
secondary carnitine deficiency [6, 7].
The study was planned to estimate GH and
insulin-like growth factor-1 (IGF-1) and their possible
relation to growth impairment in thalassaemic
patients. In addition, evaluation of the effect of 
L-carnitine treatment on growth of thalassaemic
patients with growth hormone deficiency (GHD)
was assessed.
Material and methods
P Pa at ti ie en nt ts s
Thirty  β-thalassaemic  patients  from  the
haematology clinic of Cairo University Children’s
Hospital were included in this study. All patients
were on a chronic low transfusion regimen (to keep
their  haemoglobin  level  above  9  g/dl)  and
subcutaneous Desferal 5 days/week.
Inclusion criteria included age > 3 years < 18 years
and height < –2 standard deviation score (SDS)
below the mean. Written consent from the patients
or their parents was taken to be included in the
study. Exclusion criteria included serious hepatic or
cardiac diseases and anaemia from sources other
than the main disease.
Thirty children of matching age and sex, with
constitutional short stature (height SDS < –2) and
normal growth hormone response to provocation
were included as controls.
M Me et th ho od ds s
Thorough history taking and clinical evaluation
of growth were done for all subjects. Height, sitting
height and weight were measured twice using 
a Harpenden stadiometer and electronic balance.
Other anthropometric data were calculated by the
program Growth Vision version 2.
Laboratory  investigations  were  carried  out
including complete blood count (CBC), kidney and
liver functions on a Hitachi 911 autoanalyser (Roche
Diagnostics, Mannheim, Germany), and serum
ferritin by means of particle-enhanced immuno-
nephelometry [8] using a Behring nephelometer 100
analyser (BN100) (kits supplied by Dade Behring,
Marburg, Germany). Thyroid profile (FT3, FT4, TSH)
was also done. FT3, FT4 [9] and TSH [10] were
estimated  on  Automated  Chemiluminescence
System ACS: 180 by a competitive and two site
sandwich immunoassay respectively using direct
chemiluminometric technology (Bayer Diagnostics,
Dublin, Germany).
Stimulation of GH secretion by 2 provocation
tests (clonidine and insulin tolerance test [ITT])
separated by one week interval was done. Growth
hormone was analysed by immunoradiometric
assay (IRMA) as described by Miles et al. [11]. The
dose  of  clonidine  given  before  the  test  was 
0.15 mg/m2 orally while that of insulin was 0.1 IU/kg
i.v.  In  the  ITT  test,  the  blood  glucose  should
decrease by 50% or more of the basal value or
decrease to 40 mg/dl. If no hypoglycaemia occurred
another dose of insulin (0.05 IU/kg) was given. With
adequate hypoglycaemia, peak GH levels less than
10 ng/ml indicated GHD. 
Patients with delayed puberty were primed with
sex hormones prior to GH testing. Ethinyl oestradiol
was given to girls at a dose of 20 ﾵg three times
per day for 3 days and testosterone was given to
boys at a single dose of 100 mg i.m. 3 days before
the test.
Insulin-like  growth  factor-1  (IGF-1)  was
determined  at  diagnosis  using  solid  phase
immunoradiometric assay (IRMA) [12] using kits
from Diagnostic System Laboratories Inc (DSL)
(Texas, USA). 
F Fo ol ll lo ow w- -u up p   s st tu ud dy y
Anthropometric  measurements  and  pubertal
assessment were done for all patients after 6 months.
Ten patients were found to have inadequate GH
response to both clonidine and ITT; one of them died
and another one developed chronic renal failure
before starting treatment and was excluded from the
follow-up study. The remaining eight patients received
L-carnitine treatment at a dose of 50 mg/kg/day
divided into three doses (recommended dose of 
L-carnitine is 50-100 mg/kg/day) for 6 months. They
were re-evaluated after 6 months of therapy (clinically,
anthropometrically and in the laboratory by doing
growth hormone stimulation test).
S St ta at ti is st ti ic ca al l   a an na al ly ys si is s
Statistical Package for the Social Sciences (SPSS)
software version 9.0 was used for data analysis. All
anthropometric data were expressed in standard
deviation score (SDS) applying the formula 
variable – mean
1 SD
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by using the software Growth Vision version 2
provided by Novo Nordisk Denmark. Data were
presented as mean ﾱ SD. For comparison of two
groups  Student’s  t-test  for  dependent  and
independent variables was used. Linear Pearson’s
correlation was also done. 
Results
Thirty thalassaemic patients (12 females and 18
males) were included in the study. Their mean age
was 13.8 ﾱ1.7 years (10.1-17.1 years), mean duration
of the disease was 11.1 ﾱ2.6 years (6-16 years) and
mean age of onset of the disease was 2.6 ﾱ1.6 years
(0.5-6 years). Twelve patients (40%) had sub-clinical
hypothyroidism and none were found to have
clinical hypothyroidism. Ten patients (33.3%) had
inadequate GH response (peak GH was < 10 ng/ml).
No significant difference was found between age
of patients, duration of disease, age of onset of
Desferal and serum ferritin level in patients with
and without growth hormone deficiency (p > 0.05).
Tables I and II show the comparison between
demographic, laboratory and anthropometric data
of thalassaemic patients with and without GHD and
between thalassaemic patients and patients with
constitutional short stature respectively. Follow-up
of the studied thalassaemic patients with normal
growth hormone for 6 months showed a significant
increase in height SDS and estimated mature
height (EMHt) (p < 0.05). Patients with GHD showed
no  significant  difference  in  anthropometric
measures (p > 0.05). A significant positive cor-
relation was found between height and target
height (cm) (Figure 1). Haematological data and
growth velocity of studied thalassaemic patients
with  growth  hormone  deficiency  showed  im-
provement after L-carnitine treatment (Table III).
Delta changes were higher in height (SDS and cm),
EMHt, sitting height and lower in target height –
height (SDS and cm) 6 months after L-carnitine
treatment in β-thalassaemic patients with growth
V Va ar ri ia ab bl le es s T Th ha al la as ss sa ae em mi ia a   m ma aj jo or r    C Co on ns st ti it tu ut ti io on na al l   s sh ho or rt t   s st ta at tu ur re e    P P- -v va al lu ue e
( (N N = =   3 30 0) )   M Me ea an n   ﾱ ﾱ   S SD D ( (N N   = = 3 30 0) )   M Me ea an n   ﾱ ﾱ   S SD D
Age [years] 13.8 ﾱ1.7 13.1 ﾱ3.1 0.3
Weight (SDS) –2 ﾱ0.8 –2.7 ﾱ1.1 0.005
Height (SDS) –4.1 ﾱ1.1 –3.7 ﾱ0.9 0.1
Growth velocity [cm] 2.4 ﾱ1.2 7.9 ﾱ2.5 0.0001
Growth velocity (SDS) –2.3 ﾱ2.5 4.7 ﾱ5.3 0.0001
US/LS (SDS) 0.5 ﾱ2.2 0.1 ﾱ1.5 0.2
Weight/height (SDS) 1.1 ﾱ1.9 –3.3 ﾱ1.6 0.02
EMHt [cm] 143.3 ﾱ8.8 155.4 ﾱ8.3 0.0001
Target height – height [cm] 33.9 ﾱ8.7 32.6 ﾱ15.1 0.7
Maximum GH [ng/ml] 10.7 ﾱ1.9 18.1 ﾱ6.5 0.0001
IGF-1 (SDS) –0.9 ﾱ0.3 –1.3 ﾱ1.5 0.1
GH – growth hormone, IGF-1 – insulin-like growth factor-1, US/LS – upper segment/lower segment, EMHt – estimated mature height
T Ta ab bl le e   I II I. . Comparison between demographic, anthropometric and hormonal data in patients with β-thalassaemia
and constitutional short stature
V Va ar ri ia ab bl le es s N No or rm ma al l    G Gr ro ow wt th h    P P- -v va al lu ue e
g gr ro ow wt th h h ho or rm mo on ne e
h ho or rm mo on ne e    d de ef fi ic ci ie en nc cy y   
( (n n = =   2 20 0) ) ( (n n = =   1 10 0) )
M Me ea an n   ﾱ ﾱ   S SD D M Me ea an n   ﾱ ﾱ   S SD D
Weight (SDS) –2.1 ﾱ0.8 –2.1 ﾱ0.9 0.7
Height (SDS) –4.2 ﾱ1.2 –4.1 ﾱ1.1 0.8
Target  167.6 ﾱ6.1 168.4 ﾱ5.9 0.7
height [cm]
Target  –0.3 ﾱ0.4 –0.2 ﾱ0.4 0.4
height (SDS]
Growth  2.5 ﾱ1.2 2.2 ﾱ1.2 0.5
velocity [cm]
Growth  –2.4 ﾱ2.4 –2.2 ﾱ2.9 0.9
velocity (SDS)
Sitting  –4.4 ﾱ1.7 –3.9 ﾱ1.6 0.4
height (SDS)
US/LS (SDS) 0.2 ﾱ1.9 1.2 ﾱ2.6 0.2
BMI (SDS) –0.7 ﾱ1.3 –0.9 ﾱ1.4 0.7
Free T3 [pg/ml] 2.7 ﾱ0.7 2.6 ﾱ0.9 0.8
Free T4 [ng %] 1.4 ﾱ0.4 1.5 ﾱ0.6 0.8
TSH [MIU/ml] 4 ﾱ1.9 3.3 ﾱ1.9 0.3
Maximum   11.8 ﾱ0.7 8.6 ﾱ1.9 0.0001
peak GH [ng/ml]
IGF-1 (SDS) –0.9 ﾱ0.3 –0.8 ﾱ0.4 0.8
T Ta ab bl le e   I I. .   Comparison between anthropometric and
hormonal data of patients with and without growth
hormone deficiency  
US/LS – upper segment/lower segment, BMI – body mass index 
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hormone deficiency (Table IV). No side effect of 
L-carnitine was reported from the patients except for
occasional diarrhoea at the beginning of treatment.
Discussion
Delayed or complete lack of pubertal changes
are common in both sexes of thalassaemic patients.
As  haemosiderosis  leads  to  damage  of  their
endocrine glands, it is implicated to be one of the
main  causes  of  their  growth  failure  [13].
Hypothyroidism and delayed puberty could affect
growth secretory dynamics; thus thyroid state
should be normalized before testing the GH. Also
sex hormones were recommended to be given to
patients with delayed puberty as priming [14].
We studied 30 β-thalassaemic patients with short
stature (height < –2 SDS); 12 patients (40%) had
sub-clinical hypothyroidism diagnosed by normal
free thyroxin level and elevated thyroid stimulating
hormone (TSH). This agrees with Landau et al. [15],
who reported sub-clinical hypothyroidism in 43% of
thalassaemic patients due to thyroid damage by iron
overload. None of our patients had overt primary
hypothyroidism, which agrees with other studies
that reported a low prevalence, 2.1% [16] and 3.2%
[4]. On the other hand higher prevalence of 6% [17]
has been reported. 
Ten of our thalassaemic patients (33.3%) had GH
response to stimulation lower than 10 ng/ml in two
GH  provocation  tests  (low  responders).  This
coincides with the results of Vidergor et al. [18] and
Moayeri and Oloomi [14], who reported that GHD
in  thalassaemic  patients  was  25  and  38%
respectively. On the other hand, it was higher than
that reported by De Sanctis et al. [4], who found
that the prevalence of GHD was 7.9% in males and
8.8% in females.
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F Fi ig gu ur re e   1 1. .   Correlation between height and target
height of thalassemic patients
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r = 0.5, p = 0.008
V Va ar ri ia ab bl le es s B Be ef fo or re e   L L- -c ca ar rn ni it ti in ne e    A Af ft te er r   L L- -c ca ar rn ni it ti in ne e P P- -v va al lu ue e
( (N N = =   8 8) )   M Me ea an n   ﾱ ﾱ   S SD D ( (N N = =   8 8) )   M Me ea an n   ﾱ ﾱ   S SD D
Hb [g/dl] 5.9 ﾱ0.4 6.6 ﾱ0.3 0.01
No. of blood transfusion/month 8 ﾱ2.4 6.8 ﾱ1.8 0.005
Maximum GH [ng/ml] 9.1 ﾱ1.4 16.6 ﾱ2 0.01
IGF-1 (SDS) –0.8 ﾱ0.4 0.1 ﾱ1.1 0.02
Growth velocity [cm] 2.1 ﾱ1 6.3 ﾱ1 0.01
Growth velocity (SDS) –2.8 ﾱ2.8 2.5 ﾱ4.6 0.03
Hb – haemoglobin, GH – growth hormone, IGF-1 – insulin-like growth factor-1
T Ta ab bl le e   I II II I. .   Haematological data and growth velocity of β-thalassaemic patients with growth hormone deficiency before
and after L-carnitine treatment
V Va ar ri ia ab bl le es s S Si ix x   m mo on nt th hs s   b be ef fo or re e   L L- -c ca ar rn ni it ti in ne e    S Si ix x   m mo on nt th hs s   a af ft te er r   L L- -c ca ar rn ni it ti in ne e P P- -v va al lu ue e
( (N N = =   8 8) )   M Me ea an n   ﾱ ﾱ   S SD D ( (N N = =   8 8) )   M Me ea an n   ﾱ ﾱ   S SD D
Height (SDS) –0.2 ﾱ0.3 0.3 ﾱ0.5 0.0001
Height [cm] 1.2 ﾱ0.5 5.4 ﾱ0.9 0.002
Target height – height (SDS) 0.2 ﾱ0.3 –0.3 ﾱ0.5 0.01
Target height – height [cm] –1.2 ﾱ0.5 –5.3 ﾱ0.9 0.01
EMHt [cm] –2.0 ﾱ4.0 3.0 ﾱ2.9 0.02
Sitting height (SDS) –0.2 ﾱ0.2 0.4 ﾱ0.4 0.02
US/LS (SDS) –6.3 ﾱ0.2 0.2 ﾱ0.4 0.1
BMI (SDS) 0.5 ﾱ1.4 –3.8 ﾱ1.2 0.6
Weight /height (SDS) 0.7 ﾱ1.6 0.03 ﾱ1.8 0.6
T Ta ab bl le e   I IV V. .   Delta changes of anthropometric data of growth hormone deficiency in β-thalassaemic patients 6 months
before and after L-carnitine treatment  
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There was no significant difference in age of
patients, age of start of chelation therapy and
serum ferritin between patients with and without
growth hormone deficiency, which agrees with
Moayeri and Oloomi [14], Vidergor et al. [18] and
Cavallo et al. [19]. 
In our study there was no significant difference
in anthropometric data between normal and low
GH responder groups. These data probably suggest
that GHD is not the only factor contributing to
growth  retardation  in  Egyptian  thalassaemic
patients. Other factors may be involved such as
nutrition, haemosiderosis and genetic factors [2].
No significant difference was found between IGF-1
SDS  in  our  patients  with  and  without  GHD 
(–0.9 ﾱ0.3 and –0.8 ﾱ0.4 respectively). DeLuca et al.
[20] reported that low IGF-1 in thalassaemic patients
in general could be attributed to disturbed liver
function secondary to iron overload and malnutrition.
Low IGF-1 in normal growth hormone responders
has led to the speculation of complete or partial
growth hormone insensitivity syndrome (GHIS)
rather than GHD as the most likely cause of their
growth retardation [3, 18, 21].
Follow-up of the studied thalassaemic patients
with normal growth hormone for 6 months showed
a significant increase in height SDS and estimated
mature height (EMHt) (p < 0.05). On the other hand,
patients with GHD showed no significant difference
in anthropometric measurements (p > 0.05). These
findings suggest that GH has an important role in
growth of thalassaemic patients and its deficiency
contributed to their growth impairment.
In the present study, peak GH in thalassaemic
patients was significantly lower than constitutional
short stature (CSS) (p < 0.05). This agrees with the
results of Soliman et al. [22], who found that peak
GH was significantly lower in thalassaemic patients
than CSS, and this was explained by impairment of
the hypothalamic-pituitary axis in thalassaemic
patients  secondary  to  pituitary  siderosis  and
somatotroph atrophy [13].
Although height SDS was insignificantly lower
in  thalassaemic  patients  than  in  CSS,  growth
velocity (GV) cm and SDS were significantly lower
in thalassaemic patients than CSS (p = 0.0001) and
this agrees with the results of Soliman et al. [23]. 
The estimated mature height (EMHt) of our
thalassaemic patients was significantly lower than
those of CSS (p = 0.0001). Both British and Italian
studies have suggested that a marked deceleration
in growth occurs between the age of 12-13 years in
almost all thalassaemic children. Although many of
these patients had “catch up” growth in later years,
their final height was always markedly lower than
their potential height [24].
A significant positive correlation was found
between height (cm) and target height (cm) in our
study (Figure 1). This coincides with Saka et al. [25],
who suggested that height in thalassaemic patients
is conditioned by genetic factors. 
Eight of our patients with GHD (GH < 10 ng/ml)
received  L-carnitine  for  6  months.  There  was 
a significant increase of peak GH and IGF-1 (SDS)
in  our  thalassaemic  patients  after  L-carnitine
therapy. Similar results were reported by Di Mazio
et al. [26]. Increase of G.V. after treatment from 
2.1 ﾱ1.0 to 6.3 ﾱ1.0 cm/year was also observed. This
coincides with El Beshlawy et al. [27], who reported
an increase of G.V. from 3.3 ﾱ2.1 to 4.8 ﾱ1.3 cm/year
after L-carnitine treatment.
There was a significant increase in delta changes
of height (SDS and cm), estimated mature height
and sitting height (SDS) 6 months after L-carnitine
treatment in GH deficient thalassaemic patients.
No statistically significant difference was found in
delta changes of upper segment/lower segment
(US/LS) (SDS) 6 months after L-carnitine treatment.
This coincides with the results of El Beshlawy et al.
[27], which denotes that there is a proportional
increase in upper and lower seg-ments.
There was an insignificant decrease in delta
change  of  body  mass  index  (SDS)  and
weight/height (SDS) 6 months after L-carnitine
treatment in this study. This also coincides with 
El Beshlawy et al. [27], who found a significant
decrease of body mass index (BMI) (SDS) and
weight/height SDS after L-carnitine treatment,
explained by the increase in height more than the
increase in weight.
A significant difference was found between
mean haemoglobin level and number of blood
transfusions per month before and after L-carnitine
therapy  (p <  0.05).  This  is  in  agreement  with
Yesilipek et al. [7], and El Beshalwy et al. [27, 28],
who reported a prolongation in transfusion interval
in thalassaemic patients after L-carnitine therapy.
L-carnitine is essential for normal oxidation of fats
by the mitochondria and energy production as well
as stabilizing cell membranes [29].
Susceptibility to oxidative stress is increased in
erythrocytes in β-thalassaemia major. L-carnitine
may prove beneficial in vivo by protecting the
erythrocytes in which peroxidative damage of the
cell structure is increased. L-carnitine as a butyric
acid analogue might have a stimulatory effect on
HbF synthesis. Furthermore, its anti-oxidant effects
may show additional benefit in β-thalassaemia
patients [7]. 
In conclusion, GHD is an aetiological factor in 
β-thalassaemic  patients  with  short  stature. 
L-carnitine can promote GH secretion and growth.
So we recommend the use of L-carnitine as routine
treatment in short thalassaemic patients with
growth hormone deficiency.
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